Clinical History

This is a 51-year-old male with relapse of refractory low-grade, non-Hodgkin's lymphoma.

Technique

In the Cancer Center treatment room, the patient was infused with Rituxin (250mg/m2 or 465 mg) over a four hour period. Once the infusion of Rituxin was complete, the Nuclear Medicine Technologist infused 5.0mCi of 111In-Zevalin over a 10 minute period (the infusion included a 0.22 micron filter attached to the end of the syringe).

Findings

On the 2 hour post-injection wholebody scan, there is normal distribution of the 111In-Zevalin in the heart, lungs, liver, spleen and soft tissues with no other incresed activity seen. On the 48 hour wholebody scan, again seen is normal distribution of the 111In-Zevalin in the heart, lungs, liver, spleen, with much less activity seen in the soft tissues. In addition, there is increased activity seen in the left axilla, bilateral iliac regions, right greater than left, as well as within the mid abdomen. The change in distribution from the two hour scan to the 48 hour scan demonstrates that the patient clears the activity adequately and therefore he is a candidate for the 90Y-Zevalin treatment.

Impression

  1. NORMAL DISTRIBUTION OF 111IN-ZEVALIN WITH ADEQUATE CLEARANCE FROM THE SOFT TISSUES, DEMONSTRATING THE PATIENT'S ELIGIBILITY FOR THE 90Y-ZEVALIN TREATMENT.


  2. INCREASED ACTIVITY SEEN IN THE LEFT AXILLA, BILATERAL ILIAC REGIONS, AND UPTAKE OF THE ZEVALIN IN THE MID ABDOMEN .

90Y-Zevalin Treatment

Technique and Findings

The Zevalin treatment was explained to the patient and informed, signed consent was obtained. In the Cancer Center treatment room, the patient was infused with Rituxin (250mg/m2 or 465 mg) over a four hour period. Once the infusion of Rituxin was complete, the Nuclear Medicine physician infused 32.0mCi of 90Y-Zevalin over a 10 minute period (the infusion included a 0.22 micron filter attached to the end of the syringe). The patient tolerated the infusion well with no immediate complications. The patient is to follow up with his physician.

Impression

SUCCESSFUL 90Y-ZEVALIN TREATMENT FOR LYMPHOMA